Antibody-Targeted Nanoparticles for Cancer Treatment

Carter, Thomas; Mulholland, Paul J.; Chester, Kerry

doi:10.2217/imt.16.11

Cited by 58 publications

(35 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanomaterials are not only promising sorbents but are also able to couple different molecules such as antibodies or targeting peptides. The application of antibodies has been highly developed in the field of medicine and target drug therapy [ 137 , 138 ]. Briefly, there are three ways of antibody conjugation on the surface of NPs: by adsorption, by direct covalent linkage between the surface of the NP and the antibody, or by using adapter molecules such as streptavidin and biotin.…”

Section: Nano Approaches For Mycotoxin Risk Eliminationmentioning

confidence: 99%

Nanoparticles as a Solution for Eliminating the Risk of Mycotoxins

et al. 2018

View full text Add to dashboard Cite

Mycotoxins are toxic secondary metabolites produced by certain filamentous fungi. The occurrence of mycotoxins in food and feed causes negative health impacts on both humans and animals. Clay binders, yeast cell walls, or antioxidant additives are the most widely used products for mycotoxin elimination to reduce their impact. Although conventional methods are constantly improving, current research trends are looking for innovative solutions. Nanotechnology approaches seem to be a promising, effective, and low-cost way to minimize the health effects of mycotoxins. This review aims to shed light on the critical knowledge gap in mycotoxin elimination by nanotechnology. There are three main strategies: mold inhibition, mycotoxin adsorption, and reducing the toxic effect via nanoparticles. One of the most promising methods is the use of carbon-based nanomaterials. Graphene has been shown to have a huge surface and high binding capacity for mycotoxins. Attention has also been drawn to polymeric nanoparticles; they could substitute adsorbents or enclose any substance, which would improve the health status of the organism. In light of these findings, this review gives new insights into possible future research that might overcome challenges associated with nanotechnology utilization for mycotoxin elimination from agricultural products.

show abstract

Section: Nano Approaches For Mycotoxin Risk Eliminationmentioning

confidence: 99%

Nanoparticles as a Solution for Eliminating the Risk of Mycotoxins

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Certain antibodies can also be used to suppress the function of T-reg cells. T-reg cells inhibit the function of immune killer cells, or mature the dendritic cells (DCs), to induce cell death via cytotoxic T lymphocyte (CTL) recruitment [40]. For non-specific immunotherapy, the enhanced delivery of certain adjuvants, such as cytokines, can be achieved with the help of nanoparticles to boost the immune response in conjunction with other cancer immunotherapies.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle Design Strategies for Effective Cancer Immunotherapy

et al. 2017

View full text Add to dashboard Cite

Cancer immunotherapy is a rapidly evolving and paradigm shifting treatment modality that adds a strong tool to the collective cancer treatment arsenal. It can be effective even for late stage diagnoses and has already received clinical approval. Tumors are known to not only avoid immune surveillance but also exploit the immune system to continue local tumor growth and metastasis. Because of this, most immunotherapies, particularly those directed against solid cancers, have thus far only benefited a small minority of patients. Early clinical substantiation lends weight to the claim that cancer immunotherapies, which are adaptive and enduring treatment methods, generate much more sustained and robust anticancer effects when they are effectively formulated in nanoparticles or scaffolds than when they are administered as free drugs. Engineering cancer immunotherapies using nanomaterials is, therefore, a very promising area worthy of further consideration and investigation. This review focuses on the recent advances in cancer immunoengineering using nanoparticles for enhancing the therapeutic efficacy of a diverse range of immunotherapies. The delivery of immunostimulatory agents to antitumor immune cells, such as dendritic or antigen presenting cells, may be a far more efficient tactic to eradicate tumors than delivery of conventional chemotherapeutic and cytotoxic drugs to cancer cells. In addition to its immense therapeutic potential, immunoengineering using nanoparticles also provides a valuable tool for unearthing and understanding the basics of tumor biology. Recent research using nanoparticles for cancer immunotherapy has demonstrated the advantage of physicochemical manipulation in improving the delivery of immunostimulatory agents. In vivo studies have tested a range of particle sizes, mostly less than 300 nm, and particles with both positive and negative zeta potentials for various applications. Material composition and surface modifications have been shown to contribute significantly in selective targeting, efficient delivery and active stimulation of immune system targets. Thus, these investigations, including a wide array of nanoparticles for cancer immunotherapy, substantiate the employment of nanocarriers for efficacious cancer immunotherapies.

show abstract

“…Monoclonal antibodies have had a long history as targeting ligands (Friedman et al, 2013) since they have complementarity determining regions that enable them to bind to receptors on cell surfaces with high specificity and affinity (Carter et al, 2016). However, since they are large molecules, their conjugation density capacity on the nanocarrier is substantially decreased (Yoo et al, 2019) compared to other ligands, and furthermore, they raise immunogenicity concerns (Karra and Benita, 2012).…”

Section: Active Targetingmentioning

confidence: 99%

The Design of Poly(lactide-co-glycolide) Nanocarriers for Medical Applications

Essa

Kondiah

Choonara

et al. 2020

Front. Bioeng. Biotechnol.

151

View full text Add to dashboard Cite

Polymeric biomaterials have found widespread applications in nanomedicine, and poly(lactide-co-glycolide), (PLGA) in particular has been successfully implemented in numerous drug delivery formulations due to its synthetic malleability and biocompatibility. However, the need for preconception in these formulations is increasing, and this can be achieved by selection and elimination of design variables in order for these systems to be tailored for their specific applications. The starting materials and preparation methods have been shown to influence various parameters of PLGA-based nanocarriers and their implementation in drug delivery systems, while the implementation of computational simulations as a component of formulation studies can provide valuable information on their characteristics. This review provides a critical summary of the synthesis and applications of PLGA-based systems in bio-medicine and outlines experimental and computational design considerations of these systems.

show abstract

Antibody-Targeted Nanoparticles for Cancer Treatment

Cited by 58 publications

References 134 publications

Nanoparticles as a Solution for Eliminating the Risk of Mycotoxins

Nanoparticles as a Solution for Eliminating the Risk of Mycotoxins

Nanoparticle Design Strategies for Effective Cancer Immunotherapy

The Design of Poly(lactide-co-glycolide) Nanocarriers for Medical Applications

Contact Info

Product

Resources

About